COPD education is helping a clinical research organization known as Richmond Pharmacology who specialise in early phase clinical trials. They need to recruit to a new COPD study from January 2012. Patients may qualify if they have a documented diagnosis of COPD made by their GP and are not currently prescribed inhaled corticosteroids.

What is this all about?

Richmond Pharmacology is conducting a clinical trial for a new experimental drug called FX125L. FX125L is an anti-inflammatory agent being developed for the treatment of chronic inflammatory diseases such as asthma, COPD, RA and psoriasis. It is anticipated that FX125L may be more effective and have fewer side effects compared to the current marketed drugs. This is the first time FX125L will be given to patients with chronic inflammation. The purpose of this study, therefore, is to examine the impact of treatment with such an agent in patients with a range of different diseases that share a chronic inflammatory component. The purpose of this study is also to collect information on markers, which will help us to plan future research studies, to further test the effect of this compound. The trial is being conducted at Richmond Pharmacology Ltd only.

What will happen?

This study is being conducted at their research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact them to register your interest. If you successfully pass the telephone screening you will be invited to their facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 14 to 28 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.

Study Participation

Participation for this study requires you to attend 5 outpatient visits and one residential stay of 1 night and 1 day at our clinical unit at Croydon University Hospital. This includes the screening visit (Visit 1) within 14 to 28 days before the start of the study, one residential stay of 1 night/1 day at our unit (Visit 2), 3 outpatient visits on Days 10, 42 and Day 56 (Visits 3, 4 and 5) and the final follow up visit (Visit 6) after the last dose of the study drug. Your participation in this study will last approximately 17 weeks.

Example of a study timetable:

What's in it for you?

Apart from doing something good, they will also compensate you for your time in the form of a monetary payment. You will receive £560 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £280 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations). The total amount that you could be paid for study participation is £840. You will also be compensated for your travel expenses.*

Want to find out more?

If you are interested in finding out more please send your full name, contact telephone number and email address to copd@richmondpharmacology.com

OR

Call Richmond Pharmacology Pharmaceuticals free on 020 8664 5200 (select option 1) and speak to a member of their Volunteer Recruitment Team.

A detailed information sheet is available on request.